

Tether influence on the binding properties of tRNA^{Lys}₃ ligands designed by a fragment based approach.

Roba Moumné,^a Valéry Larue,^b Bili Seijo,^b Thomas Lecourt,^a Laurent Micouin^{*a} and Carine Tisné^{*b}

Supporting Information


1. Chemistry	2
1.1. General Procedure for 2-Azido-Ketone Synthesis	2
1.2. General Procedure for RuAAC	4
1.3. General Procedure for Boc-Deprotection.....	9
1.4. Synthesis of 2-[4-chloro-6(2,4-diaminocyclopentyloxy)1,3,5-triazin-2-yloxy)-1-naphthalen-2-yl) ethanone 9	13
2. 1H and 13C NMR spectra of compounds 4, 5, 6, 8 and 9.....	16
3. Superimposition of TROSY Spectra of tRNA ^{Lys} ₃ (black) and tRNA ^{Lys} ₃ mixed with compounds 5a-5g and 10 (red).....	40

1. Chemistry

1.1. General Procedure for 2-Azido-Ketone Synthesis


NaN₃ (2 eq) was added to a solution of the α -bromo-ketone in acetone (0.5 mol/L) at room temperature. The reaction was stirred for one hour. After addition of water the product was extracted with EtOAc, dried over MgSO₄ and concentrated *in vacuo*. The crude product was purified by FC column chromatography on silica gel (Cyclohexane-AcOEt, 9:1).

2-azido-1-Phenylethanone **2a**



(oil, 322 mg, 80%); Rf (Cy/ EtOAc, 9:1) 0.31; **2a** was identified by comparison of its spectral data to the literature,¹ δ_H (300 MHz, CDCl₃): 7.90 (m, 2H, H₃); 7.62 (1H, m, H₅); 7.49 (2H, t, *J* 9 Hz, H₄); 4.56 (2H, s, H₂); δ_C (75 MHz, CDCl₃): 193.3 (s, C₁); 134.3 (s, C₂); 134.2 (d, C₅); 129.0 (d, C₃ or C₄); 127.9 (d, C₃ or C₄); 54.9 (t, C₂).


2-azido-1-(naphthalen-2-yl)ethanone **2b**



(white powder, 300 mg, 71%); Rf (Cy/ EtOAc, 9:1) 0.30; mp 60-62°C; $\nu_{\max}$ (KBr, nujol) /cm⁻¹ 3103s, 1677s, 1628w, 1421w, 1356s, 1296w, 1275w, 1257w, 1218w, 1190m, 1123w, 912w, 898m, 859m; δ_H (300 MHz, CDCl₃): 8.40 (s, 1H, H₃); 7.88-7.97 (4H, m, H₅, H₈, H₁₀, H₁₁); 7.57-7.67 (2H, m, H₆, H₇); 4.71 (2H, s, H₂); δ_C (75 MHz, CDCl₃): 193.2 (s, C₁); 136.0 (s, C₂); 132.4 (s, C₄ or C₉); 131.7 (s, C₄ or C₉); 129.8 (d, C₃); 129.6 (d, C₅); 129.1 (d, C₇); 129.0 (d, C₁₀); 127.9 (d, C₈); 127.2 (d, C₆); 123.3 (d, C₁₁); 55.0 (t, C₂); *m/z* (ESI): 234 (MNa⁺), calculated for C₁₂H₉N₃O 211.


¹ K. Edegger, C. C. Gruber, T. M. Poessl, S. R. Wallner, I. Lavandera, K. Faber, F. Niehaus, J. Eck, R. Oehrlein, A. Hafner, W. Kroutil, *Chem. Comm.* 2006, **22**, 2402.

2-azido-1-(biphenyl-4-yl)ethanone 2c




(white powder, 502 mg, 85%); Rf (Cy/ EtOAc, 9:1) 0.22; mp 92-93°C; $\nu_{\max}$ (KBr, nujol) /cm⁻¹ 2139m, 2100s, 1684s, 1604s, 1581w, 1460w, 1447w, 1420w, 1276s, 1226m, 1191w, 1116w, 1075w, 911m, 847m, 832m, 809w; δ_H (300 MHz, CDCl₃): 7.98 (2H, d, *J* 6 Hz, H₃); 7.72 (2H, d, *J* 9 Hz, H₄); 7.63 (2H, d, *J* 9 Hz, H₇); 7.26-7.52 (3H, m, H₈, H₉); 4.59 (2H, s, H_{2'}); δ_C (75 MHz, CDCl₃): 192.8 (s, C₁); 146.7 (s, C₅); 139.4 (s, C₆); 133 (s, C₂); 129.1 (d, C₈); 128.9 (d, C₉); 128.5 (d, C₃); 127.5 (d, C₄); 127.2 (d, C₇); 54.9 (t, C_{2'}); *m/z* (ESI): 260 (MNa⁺), calculated for C₁₄H₁₁N₃O 237.

2-azido-1-(thiophen-2-yl)ethanone 2d



(brown powder, 144 mg, 72%); Rf (Cy/ EtOAc, 9:1) 0.30; mp 62-64°C; $\nu_{\max}$ (KBr, nujol) /cm⁻¹ 2107s, 1658s, 1516w, 1413m, 1305w, 1234w, 1059w, 892m, 851m; δ_H (300 MHz, CDCl₃): 7.74 (1H, dd, *J* 3 Hz, *J* 1 Hz, H₅); 7.72 (1H, dd, *J* 2 Hz, *J* 1 Hz, H₃); 7.17 (1H, dd, *J* 4.9 Hz, *J* 4 Hz, H₄); 4.46 (2H, s, H_{2'}); δ_C (75 MHz, CDCl₃): 186.3 (s, C₁); 140.0 (s, C₂); 135.0 (d, C₅); 132.5 (d, C₄); 128.5 (d, C₃); 54.9 (t, C_{2'}); *m/z* (ESI): 190 (MNa⁺), calculated for C₆H₅N₃OS 167.


2-azido-1-(5-methyl-1-phenyl-1H-pyrazol-4-yl)ethanone 2e



(white powder, 167 mg, 77%); Rf (Cy/ EtOAc, 9:1) 0.30; mp 88-89°C; $\nu_{\max}$ (KBr, nujol) /cm⁻¹ 2128m, 2105s, 1677s, 1600w, 1551m, 1504m, 1407w, 1331w, 1264m, 1221m, 1193w, 1173w, 995w, 938w, 908m, 871w; δ_H (300 MHz, CDCl₃): 7.96 (1H, s, H₃); 7.46-7.55 (3H, m); 7.38-7.44 (2H, m); 7.35 (2H, m, H_{2'}); 2.60 (3H, s, H₅); δ_C (75 MHz, CDCl₃): 188.7 (s,


C₁); 144.2 (s, C₂); 140.4 (d, C₃); 138.2 (s, C₆); 129.4 (d); 129 (d); 125.5 (d); 117.9 (s, C₄); 55.7 (t, C_{2'}); 12.5 (q, C₅); *m/z* (ESI): 264 (MNa⁺), calculated for C₁₂H₁₁N₅O 241.

2-azido-1-(5-(pyridin-2-yl)thiophen-2-yl)ethanone 2f



(white powder, 191 mg, 88%); mp 151-155°C; δ_H (300 MHz, CDCl₃): 8.63 (1H, d, *J* 4.2 Hz, H₁₀); 7.61-7.79 (4H, m, H₃, H₄, H₇, H₈); 7.35 (1H, m, H₉); 4.46 (2H, m, H_{2'}); 2.60 (3H, s, H₅); δ_C (75 MHz, CDCl₃): 188.7 (s, C₁); 144.2 (s, C₂); 140.4 (d, C₃); 138.2 (d, C₆); 129.4 (d); 129.0 (d); 125.5 (d); 117.9 (s, C₄); 55.7 (t, C_{2'}); 12.5 (q, C₅); *m/z* (ESI): 267 (MNa⁺), calculated for C₁₁H₈N₄OS 244.

2-azido-1-(benzothiophen-yl)ethanone 2g




(white powder, 189 mg, 89%); *R_f* (Cy/ EtOAc, 8:2) 0.64; mp 113-115°C; $\nu_{\max}$ (KBr, nujol) /cm⁻¹ 2097s, 1685s, 1587w, 1417w, 1341w, 1317w, 1278w, 1221m, 1170w, 1154m, 1094w, 1057m, 931w, 920m, 908m, 882w, 820m, 800w; δ_H (300 MHz, CDCl₃): 8.34 (1H, s, H₃); 7.97 (1H, d, *J* 8.9 Hz, H₈); 7.87 (1H, d, *J* 8.9 Hz, H₉); 7.56 (1H, d, *J* 5.9 Hz, H₆); 7.45 (1H, d, *J* 4.9 Hz, H₅); 4.65 (3H, s, H_{2'}); δ_C (75 MHz, CDCl₃): 193.1 (s, C₁); 145.2 (s, C₇); 139.5 (s, C₄); 130.9 (s, C₂); 128.5 (d, C₉); 124.6, 124.0, 123.1, 122.9 (d, C₃, C₅, C₆, C₈); 55.0 (t, C_{2'}); *m/z* (ESI): 240 (MNa⁺), calculated for C₁₀H₇N₃OS 217.

1.2. General Procedure for RuAAC

Cp*RuCl(COD) (5 mg, 4 mol%) was introduced into a two-necked flask and the flask was evacuated under vacuum and filled with nitrogen three times. After addition of dried THF (1 mL), a solution of DACP (100 mg, 0.29 mmol) in THF (2 mL) and a solution of the azido-ketone (0.29 mmol) in THF (2 mL) were added successively. The reaction was stirred for one


hour. The solution was concentrated *in vacuo* and the crude product was purified by FC column chromatography on silica gel (Cyclohexane-AcOEt, 4:6).

***tert*-butyl-4-((1-(2-oxo-2-phenylethyl)-1*H*-1,2,3-triazol-5-yl)methoxy)cyclopentane-1,3-dicarbamate 4a**




(powder, 116 mg, 80%); *R*_f (Cy/ EtOAc, 4:6) 0.33; mp 68-72°C; ν_{max} (KBr, nujol) /cm⁻¹ 3334br, 1694s, 1598w, 1515s, 1298w, 1250w, 1165m, 1071w, 1001w, 861w; δ_{H} (300 MHz, CDCl₃): 8.03 (2H, dd, *J* 1.3 Hz, 7 Hz, H₁₂); 7.68 (1H, s, H₈); 7.66 (1H, tt, *J* 2 Hz, 7 Hz, H₁₄); 7.54 (2H, t, *J* 7 Hz, H₁₃); 6.04 (1H, d (AB), *J* 18 Hz, H₉); 5.92 (1H, d (AB), *J* 18 Hz, H₉); 5 (1H, br s, NH); 4.73 (1H, br s, NH); 4.67 (1H, d (AB), *J* 11 Hz, H₆); 4.59 (1H, d (AB), *J* 11 Hz, H₆); 3.86 (1H, m, H₄); 3.78-3.80 (1H, m, H₂); 3.69 (1H, dt, *J* 3 Hz, *J* 6 Hz, H₁); 2.39 (1H, dt, *J* 8 Hz, *J* 15 Hz, H₃); 1.84 (1H, ddd, *J* 3 Hz, *J* 7 Hz, *J* 13 Hz, H₅); 1.69-1.76 (1H, m, H₅); 1.43 (18H, s); 1.29 (1H, dt, *J* 7 Hz, *J* 15 Hz, H₃); δ_{C} (75 MHz, CDCl₃): 190.8 (s, C₁₀); 155.3 (s, CO_{Boc}); 134.7 (s, C₇); 134.4 (d, C₁₄); 134.2 (d, C₁₁); 134.0 (d, C₈); 129.2 (d, C₁₂ or C₁₃); 128.3 (d, C₁₂ or C₁₃); 83.7 (d, C₁); 79.6 (s, C_{iv} Boc); 59.3 (t, C₆); 55.6 (d, C₂); 54.7 (t, C₉); 49.4 (d, C₄); 37.3 (t, C₃ and C₅); 26.9 (q, C_{tBu}); *m/z* (ESI): 538 (MNa⁺), calculated for C₂₆H₃₇N₅O₆ 515.

***tert*-butyl-4-((1-(2-oxo-2-naphthylethyl)-1*H*-1,2,3-triazol-5-yl)methoxy)cyclopentane-1,3-dicarbamate 4b**



(powder, 104 mg, 66%); R_f (Cy/ EtOAc, 4:6) 0.45; mp 90-92°C; $\nu_{\max}$ (KBr, nujol) /cm⁻¹ 3333br, 1694s, 1515s, 1366m, 1297w, 1276w, 1254w, 1167m, 1125w, 1072w, 1008w, 861w, 823w; δ_H (300 MHz, CDCl₃): 8.60 (1H, s, H₁₂); 8.02-8.06 (2H, m, H₁₄, H₂₀); 7.89-7.97 (2H, m, H₁₇, H₁₉); 7.71 (1H, s, H₈); 7.66 (1H, td, *J* 3 Hz, *J* 9 Hz, H₁₆); 7.60 (1H, td, *J* 3 Hz, *J* 6 Hz, H₁₅); 6.20 (1H, d (AB), *J* 18 Hz, H₉); 6.06 (1H, d (AB), *J* 18 Hz, H₉); 4.96 (1H, br s, NH); 4.75 (2H, d (AB) + br s, *J* 13 Hz, H₆, NH); 4.66 (1H, d (AB), *J* 13 Hz, H₆); 3.87 (1H, m, H₄); 3.73-3.78 (1H, m, H₂); 3.71 (1H, dt, *J* 3 Hz, 6 Hz, H₁); 2.38 (1H, dt, *J* 8 Hz, 14 Hz, H₃); 1.86 (1H, ddd, *J* 3 Hz, 8 Hz, 14 Hz, H₅); 1.60-1.69 (1H, m, H₅); 1.42 (18H, s); 1.29 (1H, dt, *J* 7 Hz, 14 Hz, H₃); δ_C (75 MHz, CDCl₃): 190.8 (s, C₁₀); 155.3 (s, CO_{Boc}); 136.1 (s, C₁₁); 134.8 (s, C₇); 133.9 (d, C₈); 132.4 (s, C₁₃ or C₁₈); 131.4 (s, C₁₃ or C₁₈); 130.4 (d, C₁₂); 129.8 (d, C₁₄); 129.2 (d, C₁₆ or C₁₉); 129.1 (d, C₁₆ or C₁₉); 127.9 (d, C₁₇); 127.2 (d, C₁₅); 123.3 (d, C₂₀); 83.8 (d, C₁); 79.5 (s, C_{iv Boc}); 59.3 (t, C₆); 55.5 (d, C₂); 54.7 (t, C₉); 49.3 (d, C₄); 37.2 (2 x t, C₃ and C₅); 28.4 (q, C_{tBu}); *m/z* (ESI): 588 (MNa⁺), calculated for C₃₀H₃₉N₅O₆ 565.


tert*-butyl-4-((1-(2-oxo-2-(1,1'-biphenyl-4-yl)ethyl)-1*H*-1,2,3-triazol-5-yl)methoxy) cyclopentane -1,3-dicarbamate **4c*



(powder, 105 mg, 63%); R_f (Cy/ EtOAc, 4:6) 0.33; mp 96-98°C; $\nu_{\max}$ (KBr, nujol) /cm⁻¹ 3334br, 1694s, 1604w, 1515m, 1505m, 1297w, 1234w, 1164w, 1073w, 998w, 843w; δ_H (300 MHz, CDCl₃): 8.12 (2H, d, *J* 6 Hz, H₁₂); 7.77 (2H, d, *J* 9 Hz, H₁₃); 7.71 (1H, s, H₈); 7.62-7.67 (2H, m, H₁₆); 7.42-7.53 (3H, m, H₁₇, H₁₈); 6.09 (1H, d (AB), *J* 18 Hz, H₉); 5.97 (1H, d (AB), *J* 18 Hz, H₉); 4.97-4.99 (1H, br s, NH); 4.75 (1H, d (AB), *J* 15 Hz, H₆); 4.66 (2H, d (AB) + br s, *J* 15 Hz, H₆, NH); 3.89 (1H, m, H₄); 3.79-3.81 (1H, m, H₂); 3.72 (1H, dt, *J* 3 Hz, 6 Hz, H₁); 2.42 (1H, dt, *J* 7.5 Hz, 15 Hz, H₃); 1.84-1.91 (1H, m, H₅); 1.60-1.79 (1H, m, H₅); 1.43 (18H, s); 1.33 (1H, dt, *J* 6 Hz, 15 Hz, H₃); δ_C (75 MHz, CDCl₃): 190.4 (s, C₁₀); 155.2 (s, CO_{Boc}); 147.1 (s, C₁₄); 139.5 (s, C₁₅); 134.6 (s, C₇); 134.0 (d, C₈); 132.8 (s, C₁₁); 129.1 (d, C₁₂ or C₁₇); 128.8 (d, C₁₂ or C₁₇); 128.6 (d, C₁₈); 127.7 (d, C₁₃ or C₁₆); 127.3 (d, C₁₃ or C₁₆); 83.7 (d, C₁);


79.7 (s, C_{iv} Boc); 59.3 (t, C₆); 55.6 (d, C₂); 54.7 (t, C₉); 49.3 (d, C₄); 37.3 (t, C₃ and C₅); 28.4 (q, C_{tBu}); *m/z* (ESI): 614 (MNa⁺), calculated for C₃₂H₄₁N₅O₆ 591.

***tert*-butyl-4-((1-(2-oxo-2-thienylethyl)-1*H*-1,2,3-triazol-5-yl)methoxy)cyclopentane-1,3-dicarbamate 4d**



(powder, 74 mg, 51%); R_f (Cy/ EtOAc, 4:6) 0.31; mp 88-90°C; δ_H (300 MHz, CDCl₃): 7.87 (1H, d, *J* 4 Hz, H₁₄); 7.74 (1H, d, *J* 4.8 Hz, H₁₂); 7.63 (1H, s, H₈); 7.19 (1H, dd, *J* 4.8 Hz, *J* 4 Hz, H₁₃); 5.93 (1H, d (AB), *J* 17.5 Hz, H₉); 5.83 (1H, d (AB), *J* 17.5 Hz, H₉); 5.21 (1H, br s, NH); 4.98 (1H, br s, NH); 4.69 (1H, d (AB), *J* 13 Hz, H₆); 4.62 (1H, d (AB), *J* 13 Hz, H₆); 3.78-3.88 (2H, m, H₄, H₂); 3.67-3.69 (1H, m, H₁); 2.37 (1H, dt, *J* 8 Hz, 13.8 Hz, H₃); 1.79-1.82 (1H, m, H₅); 1.70-1.75 (1H, m, H_{5'}); 1.26-1.42 (19H, m, CH₃ (tBu), H_{3'}); δ_C (75 MHz, CDCl₃): 183.8 (s, C₁₀); 155.2 (s, CO_{Boc}); 140.4 (s, C₁₁); 135.4 (d, C₁₄); 134.7 (s, C₇); 133.9 (d, C₈); 133.2 (d, C₁₃); 128.7 (d, C₁₂); 83.8 (d, C₁); 79.5 (s, C_{iv} Boc); 59.3 (t, C₆); 55.5 (d, C₂); 54.5 (t, C₉); 49.3 (d, C₄); 37.2 (t, C₃ and C₅); 28.4 (q, C_{tBu}); *m/z* (ESI): 544 (MNa⁺), calculated for C₂₄H₃₅N₅O₆S 521.


***tert*-butyl-4-((1-(2-oxo-2-(5-methyl-1-phenylpyrazol-4-yl)ethyl)-1*H*-1,2,3-triazol-5-yl)methoxy)cyclopentane-1,3-dicarbamate 4e**



(Powder, 100 mg, 60%); R_f (Cy/ EtOAc, 4:6) 0.26; mp 86-90°C; δ_H (300 MHz, CDCl₃): 8.15 (1H, s, H₁₂); 7.67 (1H, s, H₈); 7.42-7.55 (5H, m, H₁₆, H₁₇, H₁₈); 5.84 (1H, d (AB), *J* 17 Hz, H₉); 5.73 (1H, d (AB), *J* 17 Hz, H₉); 5.08 (1H, br s, NH); 4.81 (1H, br s, NH); 4.73 (1H, d


(AB), J 13.6 Hz, H_6); 4.65 (1H, d (AB), J 13.6 Hz, H_6); 3.81-3.95 (2H, m, H_4 , H_2); 3.71-3.73 (1H, m, H_1); 2.60 (3H, s, H_{14}); 2.44 (1H, dt, J 8 Hz, J 13.6 Hz, H_3); 1.87-1.94 (1H, m, H_5); 1.70-1.79 (1H, m, H_5); 1.24-1.42 (19H, m, CH_3 (tBu), H_3); δ_C (75 MHz, $CDCl_3$): 186.0 (s, C_{10}); 155.2 (s, CO_{Boc}); 144.5 (s, C_{11}); 140.7 (s, C_{13}); 138.2 (s, C_{15}); 134.7 (s, C_7); 134.0 (d, C_8); 129.4 (d, C_{16} or C_{17}); 129.2 (d, C_{18}); 125.6 (d, C_{16} or C_{17}); 117.8 (d, C_{12}); 83.7 (d, C_1); 79.6 (s, $C_{iv Boc}$); 59.3 (t, C_6); 55.6 (d, C_2); 55.4 (t, C_9); 49.5 (d, C_4); 37.2 (t, C_3 and C_5); 28.4 (q, C_{tBu}); 12.5 (q, C_{14}); m/z (ESI): 618 (MNa^+), calculated for $C_{30}H_{41}N_7O_6$ 595.

***tert*-butyl-4-((1-(2-oxo-2-(5-(pyridin-2-yl)thiophen-2-yl)ethyl)-1*H*-1,2,3-triazol-5-yl) methoxy) cyclopentane-1,3-dicarbamate 4f**



(powder, 73 mg, 44%); R_f (Cy/ EtOAc, 4:6) 0.25; mp 113-115°C; ν_{max} (KBr, nujol) $/cm^{-1}$ 3327br, 1686s, 1583w, 1510m, 1430m, 1365m, 1295w, 1243m, 1164m, 1076w, 995w; δ_H (300 MHz, $CDCl_3$): 8.61 (1H, dt, J 7.5 Hz, 1.5 Hz, H_{16}); 7.86 (1H, d, J 7.5 Hz, H_{12}); 7.71-7.79 (2H, m, H_{17} , H_{18}); 7.66 (1H, s, H_8); 7.63 (1H, d, J 7.5 Hz, H_{13}); 7.27 (1H, ddd, J 7.5 Hz, 7.5 Hz, 1.5 Hz, H_{17}); 5.92 (1H, d (AB), J 15 Hz, H_9); 5.84 (1H, d (AB), J 15 Hz, H_9); 5.1 (1H, br s, NH); 4.82-4.84 (1H, br s, NH); 4.73 (1H, d (AB), J 15 Hz, H_6); 4.65 (1H, d (AB), J 15 Hz, H_6); 3.79-3.91 (2H, m, H_4 , H_2); 3.69-3.73 (1H, m, H_1); 2.40 (1H, dt, J 9 Hz, 12 Hz, H_3); 1.71-1.89 (2H, m, H_5); 1.29-1.43 (19H, m, CH_3 (tBu), H_3); δ_C (75 MHz, $CDCl_3$): 183.8 (s, C_{10}); 155.3 (s, CO_{Boc}); 154 (s, C_{14}); 151 (s, C_{15}); 150 (d, C_{16}); 140.6 (d, C_{11}); 137.1 (d, C_{18}); 134.7 (s, C_7); 134 (d, C_8 and C_{12}); 125.4 (d, C_{13}); 123.7 (d, C_{17}); 119.8 (d, C_{19}); 83.9 (d, C_1); 79.5 (s, $C_{iv Boc}$); 59.4 (t, C_6); 55.6 (d, C_2); 55.5 (t, C_9); 49.4 (d, C_4); 37.3 (t, C_3 and C_5); 28.4 (q, C_{tBu}); m/z (ESI): 621 (MNa^+), calculated for $C_{29}H_{38}N_6O_6S$ 598.

***tert*-butyl-4-((1-(2-(benzothiophen-5-yl)-2-oxoethyl)-1*H*-1,2,3-triazol-5-yl)methoxy)cyclopentane-1,3-dicarbamate 4g**




(powder, 123 mg, 74%); R_f (Cy/ EtOAc, 4:6) 0.36; mp 132-136°C; δ_H (300 MHz, CDCl₃): 8.53 (1H, s, H₁₂); 7.95-8.02 (2H, m, H₁₇, H₁₈); 7.7 (1H, s, H₈); 7.58 (1H, d, *J* 5.3 Hz, H₁₅); 7.49 (1H, d, *J* 5.3 Hz, H₁₄); 6.15 (1H, d (AB), *J* 18 Hz, H₉); 6.01 (1H, d (AB), *J* 18 Hz, H₉); 5.1 (1H, br s, NH); 4.62-4.71 (3H, m, NH and H₆); 3.69-3.90 (2H, m, H₄, H₂, H₁); 2.38 (1H, dt, *J* 8 Hz, *J* 14 Hz, H₃); 1.71-1.88 (2H, m, H₅); 1.27-1.43 (19H, m, CH₃ (tBu), H₃); δ_C (75 MHz, CDCl₃): 190.7 (s, C₁₀); 155.3 (s, CO_{Boc}); 145.3 (s, C₁₆); 139.6 (s, C₁₃); 134.7 (s, C₇); 134 (d, C₈); 130.7 (s, C₁₁); 128.5 (d, C₁₅); 124.8 (d, C₁₄); 124.4 (d, C₁₂); 123.3 (d, C₁₇ or C₁₈); 123 (d, C₁₇ or C₁₈); 83.7 (d, C₁); 79.7 (s, C_{iv Boc}); 59.4 (t, C₆); 55.6 (d, C₂); 54.8 (t, C₉); 49.5 (d, C₄); 37.4 (t, C₃ and C₅); 28.4 (q, C_{tBu}); *m/z* (ESI): 594 (MNa⁺), calculated for C₂₈H₃₇N₅O₆S 571.

1.3. General Procedure for Boc-Deprotection

A solution of the Boc-protected triazole derivative was cooled in an ice-bath and HCl (g) was bubbled inside until the formation of a white precipitate (few minutes). The solution was concentrated *in vacuo*.


4-((1-(2-oxo-2-phenylethyl)-1*H*-1,2,3-triazol-5-yl)methoxy)cyclopentane-1,3-diamine chloride 5a



(Powder, 60 mg); R_f (BuOH/ AcOH/ H₂O, 4:1:5) 0.12; mp 162-164°C; UV absorptions: λ_{max} (H₂O)/nm 250 and 290; δ_H (300 MHz, CD₃OD): 8.15-8.17 (2H, m, H₁₂); 8.05 (1H, s, H₈); 7.73-7.77 (1H, m, H₁₄); 7.62 (2H, m, H₁₃); 6.26 (2H, s, H₉); 4.79 (2H, s, H₆); 4.26 (1H, m, H₁); 3.58-3.62 (1H, m, H₄); 3.46 (1H, m, H₂); 2.56 (1H, m, H₃); 2.14 (2H, m, H₅); 1.80 (1H,


m, H₃); δ_{C} (75 MHz, CD₃OD): 193.1 (s, C₁₀); 136.0 (d, C₁₄); 135.5 (s, C₁₁); 130.5 (d, C₁₂ or C₁₃); 129.8 (d, C₁₂ or C₁₃); 81.9 (d, C₁); 61.4 (t, C₆); 56.5 (d and t, C₂ and C₉); 48.6 (d, C₄); 35.5 (t, C₅); 34.2 (t, C₃); m/z (HRMS ESI): 316.1768 (MH⁺), calculated for C₁₆H₂₂N₅O₂ 316.1768.

4-((1-(2-oxo-2-naphtylethyl)-1H-1,2,3-triazol-5-yl)methoxy)cyclopentane-1,3-diamine chloride 5b



(Powder, 58 mg); R_f (BuOH/ AcOH/ H₂O, 4:1:5) 0.2; mp 176-179°C; UV absorptions: λ_{max} (H₂O)/nm 290 and 350; δ_{H} (300 MHz, CD₃OD): 8.86 (1H, s, H₁₂); 7.99-8.17 (5H, m, H₈, H₁₄, H₁₇, H₁₉, H₂₀); 7.64-7.74 (2H, m, H₁₅, H₁₆); 6.39 (2H, s, H₉); 4.81 (2H, s, H₆); 4.25 (1H, dt, J 5.8 Hz, J 11.5 Hz, H₁); 3.62-3.67 (1H, m, H₄); 3.42-3.50 (1H, m, H₂); 2.55 (1H, dt, J 7.1 Hz, J 13.2 Hz, H₃); 2.11-2.16 (2H, m, H₅); 1.78 (1H, dt, J 10 Hz, J 13.1 Hz, H₃); δ_{C} (75 MHz, CD₃OD): 193 (s, C₁₀); 137.8 (s); 134.1 (d (C₈) and s); 132.7 (s); 132.4 (d); 131.1 (d); 130.8 (d); 130.3 (d); 129.2 (d); 128.6 (d); 124.4 (d); 81.9 (d, C₁); 61.3 (t, C₆); 56.6 (d, C₉); 56.4 (t, C₂); 48.4 (d, C₄); 35.4 (t, C₅); 34.1 (t, C₃); m/z (HRMS ESI): [MH⁺] 366.1925 (Calculated for C₂₀H₂₄N₅O₂ 366.1925).


4-((1-(2-oxo-2-(1,1'-biphenyl-4-yl)ethyl)-1H-1,2,3-triazol-5-yl)methoxy)cyclopentane-1,3-diamine chloride 5c



(Powder, 37 mg); R_f (BuOH/ AcOH/ H₂O, 4:1:5) 0.28; mp 169-171°C; UV absorptions: λ_{max} (H₂O)/nm 290; δ_{H} (300 MHz, CD₃OD): 8.24 (2H, d, J 8 Hz, H₁₂); 8.23 (1H, s, H₈); 7.89 (2H, d, J 7 Hz, H₁₃); 7.73 (2H, d, J 7 Hz, H₁₆); 7.41-7.53 (3H, m, H₁₇, H₁₈); 6.36 (2H, s, H₉); 4.85 (2H, s, H₆); 4.30 (1H, m, H₁); 3.68 (1H, m, H₄); 3.51 (1H, m, H₂); 2.59 (1H, m, H₃); 2.18 (2H, m, H₅); 1.80-1.84 (1H, m, H₃); δ_{C} (75 MHz, CD₃OD): 192.5 (s, C₁₀); 148.7 (s, C₁₄); 140.7 (s, C₁₅); 134.0 (s, C₁₁); 130.5 (d, C₁₂ or C₁₇); 130.3 (d, C₁₂ or C₁₇); 129.9 (d, C₁₈); 128.8


(d, C₁₃ or C₁₆); 128.4 (d, C₁₃ or C₁₆); 81.9 (d, C₁); 61.3 (t, C₆); 56.9 (t, C₉); 56.4 (d, C₂); 48.5 (d, C₄); 35.4 (t, C₅); 34.2 (t, C₃); *m/z* (HRMS ESI): [MH]⁺ 392.2081 (Calculated for C₂₂H₂₆N₅O₂ 392.2081).

4-((1-(2-oxo-2-(thiophenyl-2-yl)ethyl)-1*H*-1,2,3-triazol-5-yl)methoxy)cyclopentane-1,3-diamine chloride 5d




(Powder, 36 mg); *R_f* (BuOH/ AcOH/ H₂O, 4:1:5) 0.05; mp 176°C; UV absorptions: λ_{max}(H₂O)/nm 265 and 295; δ_H (300 MHz, CD₃OD): 8.21 (1H, d, *J* 3.7 Hz, H₁₄); 8.06 (1H, s, H₈); 8.04 (1H, d, *J* 5.4 Hz, H₁₂); 7.34 (1H, dd, *J* 3.8 Hz, *J* 5 Hz, H₁₃); 6.2 (2H, s, H₉); 4.81 (2H, s, H₆); 4.26 (1H, m, H₁); 3.58-3.66 (1H, m, H₄); 3.43-3.50 (1H, m, H₂); 2.57 (1H, dt, *J* 6.8 Hz, *J* 13.8 Hz, H₃); 2.13-2.17 (2H, m, H₅); 1.81 (1H, dt, *J* 9.4 Hz, *J* 13.4 Hz, H_{3'}); δ_C (75 MHz, CD₃OD): 186.1 (s, C₁₀); 141.6 (s, C₁₁); 137.6 (d, C₁₄); 137.4 (s, C₇); 136.0 (d, C₁₃); 134.0 (d, C₈); 130.4 (d, C₁₂); 82.9 (d, C₁); 61.1 (t, C₆); 56.4 (d, C₂); 56.1 (t, C₉); 48.7 (d, C₄); 35.3 (d, C₅); 34.2 (t₂, C₃); *m/z* (HRMS ESI): [MH]⁺ 322.1327 (Calculated for C₁₄H₂₀N₅O₂S: 322.1321).

4-((1-(2-(5-methyl-1-phenyl-1*H*-pyrazol-4-yl)-2-oxoethyl)-1*H*-1,2,3-triazol-5-yl)methoxy)cyclopentane-1,3-diamine chloride 5e




(Powder, 34 mg); *R_f* (BuOH/ AcOH/ H₂O, 4:1:5) 0.16; mp 182°C; UV absorptions: λ_{max}(H₂O)/nm 255; δ_H (300 MHz, CD₃OD): 8.47 (1H, s, H₁₂); 8.30 (1H, s, H₈); 7.52-7.61 (5H, m, H₁₆, H₁₇, H₁₈); 6.16 (2H, s, H₉); 4.87 (2H, s, H₉); 3.34 (1H, m, H₁); 3.76 (1H, m, H₄); 3.60 (1H, m, H₂); 2.66 (1H, m, H₃); 2.58 (3H, s, H₁₄); 2.22 (2H, m, H₅); 1.87 (1H, m, H_{3'}); δ_C (75 MHz, CD₃OD): 187.8 (s, C₁₀); 146.3 (s, C₁₁); 142.8 (s, C₁₃); 139.5 (s, C₁₅); 130.8 (d, C₁₆ or C₁₇); 130.7 (d, C₁₈); 127.1 (d, C₁₆ or C₁₇); 119.0 (d, C₁₂); 81.8 (d, C₁); 61.2 (t, C₆); 57.4 (t, C₉); 56.5 (d, C₂); 48.9 (d, C₄); 35.4 (t, C₅); 34.2 (t, C₃); 12.8 (q, C₁₄); *m/z* (HRMS ESI): [MH]⁺ 396.2142 (Calculated for C₂₀H₂₆N₇O₂ 396.2142).

4-((1-(2-oxo-2-(5-(pyridin-2-yl)thiophen-2-yl)ethyl)-1H-1,2,3-triazol-5-yl) methoxy) cyclopentane-1,3-diamine chloride 5f



(Powder, 31 mg); R_f (BuOH/ AcOH/ H₂O, 4:1:5) 0.13; mp 194-195°C; UV absorptions: λ_{max}(H₂O)/nm 336; δ_H (300 MHz, CD₃OD): 8.83 (1H, d, *J* 5 Hz, H₁₆); 8.57 (1H, t, *J* 8 Hz, H₁₈); 8.42 (1H, d, *J* 8 Hz, H₁₉); 8.37 (1H, d, *J* 4 Hz, H₁₂); 8.18 (1H, d, *J* 4 Hz, H₁₃); 8.12 (1H, s, H₈); 7.97 (1H, t, *J* 6 Hz, H₁₇); 6.34 (2H, s, H₉); 4.86 (2H, s, H₆); 4.30-4.32 (1H, m, H₁); 3.68-3.71 (1H, m, H₄); 3.53-3.58 (1H, m, H₂); 2.61-2.66 (1H, m, H₃); 2.17-2.21 (2H, m, H₅); 1.80-1.85 (1H, m, H₃); δ_C (75 MHz, CD₃OD): 186.2 (s, C₁₀); 147.6 (s, C₁₄); 147.1 (d, C₁₆); 145.5 (s, C₁₅); 145.1 (d, C₁₈); 144.6 (s, C₁₁); 137.9 (s, C₇); 136.7 (d, C₁₂); 133.8 (d, C₈); 132.5 (d, C₁₃); 127.5 (d, C₁₇); 126.4 (d, C₁₉); 82.1 (d, C₁); 62.1 (t, C₆); 56.4 (d, C₂); 56.4 (t, C₉); 49 (d, C₄); 35.5 (t, C₅); 34.2 (t, C₃); *m/z* (HRMS ESI): [MH]⁺ 399.1598 (Calculated for C₁₉H₂₃N₆O₂S 399.1598).

4-((1-(2-(benzothiophen-5-yl)-2-oxoethyl)-1H-1,2,3-triazol-5-yl)methoxy) cyclopentane-1,3-diamine chloride 5g




(Powder, 89 mg); R_f (BuOH/ AcOH/ H₂O, 4:1:5) 0.19; mp 142-146°C; UV absorptions: λ_{max}(H₂O)/nm 255 and 295; δ_H (400 MHz, CD₃OD): 8.74 (1H, s, H₁₂); 8.30 (1H, s, H₈); 8.12 (1H, d, *J* 8.8 Hz, H₁₇ or H₁₈); 8.05 (1H, d, *J* 8.4 Hz, H₁₇ or H₁₈); 7.78 (1H, d, *J* 5.3 Hz, H₁₅); 7.62 (1H, d, *J* 5.3 Hz, H₁₄); 6.45 (2H, s, H₉); 4.87 (2H, s, H₆); 4.30-4.32 (1H, m, H₁); 3.64-3.68 (1H, m, H₄); 3.50-3.52 (1H, m, H₂); 2.56-2.62 (1H, m, H₃); 2.17-2.20 (2H, m, H₅); 1.78-1.86 (1H, m, H₃); δ_C (100 MHz, CD₃OD): 192.5 (s, C₁₀); 147.3 (s, C₁₆); 141.2 (s, C₁₃); 133 (d, C₈); 131.7 (s, C₁₁); 130.3 (d, C₁₅); 126.2 (d, C₁₂ or C₁₄); 126.1 (d, C₁₂ or C₁₄); 124.5 (d, C₁₇ or C₁₈); 124.2 (d, C₁₇ or C₁₈); 82.0 (d, C₁); 61.1 (t, C₆); 57.4 (t, C₉); 56.3 (d, C₂); 48.5 (d, C₄);

35.4 (t, C₅); 34.1 (t, C₃); *m/z* (HRMS ESI): [MH]⁺ 372.1489 (Calculated for C₁₈H₂₂N₅O₂S 372.1489).


1.4. Synthesis of 2-[4-chloro-6(2,4-diaminocyclopentyloxy)1,3,5-triazin-2-yloxy)-1-naphthalen-2-yl) ethanone 10

Tert-Butyl-4-[4,6-dichloro-1,3,5-triazin-2-yloxy) cyclopentane-1,3-diylldicarbamate 7



To a solution of cyanuric chloride (369 mg, 2 mmol) in freshly distilled dichloroethane (5 mL) are successively added DACP (316 mg, 1 mmol) and K₂CO₃ (276 mg, 2 mmol). The reaction mixture is refluxed for 24 h. After addition of brine solution, the mixture is extracted with DCM. The combined organic layers are washed with brine, dried (MgSO₄) and concentrated *in vacuo*. The crude mixture is submitted to FC on silica gel (Cyclohexane-AcOEt, 8:2) giving compound 7 as a white powder (36% yield); R_f (Cy/ EtOAc, 6:4) 0.63; mp 104-106°C; δ_H (300 MHz, CDCl₃): 5.51-5.52 (1H, m, H₁); 5.29 (1H, br s, NH); 4.99 (1H, br s, NH); 3.97-4.1 (2H, m, H₂, H₄); 2.60 (1H, dt, *J* 8.3 Hz, *J* 13.8 Hz, H₃); 2.14-2.22 (2H, m, H₅); 1.62-1.65 (1H, m, H₃); 1.42 (18H, s, CH₃ (tBu)); δ_C (75 MHz, CDCl₃): 172.5 (s, C₇ and C₈); 170.5 (s, C₆); 155.3 (s, CO_{Boc}); 84.4 (d, C₁); 79.8 (s, C_{iv} Boc); 55.9 (d, C₂); 48.6 (d, C₄); 36.8 (t, C₃ and C₅); 28.4 (q, C_{tBu}); *m/z* (ESI): 464 (MH⁺), 486 (MNa⁺), calculated for C₁₈H₂₇Cl₂N₅O₅ 463.


2-Hydroxy-1-(naphthalen-2-yl)ethanone 8



To a mixture of TFA (930 μ L, 12 mmol), H₂O (6 mL) and acetonitrile (30 mL) was added acetophenone (1 g, 5.9 mmol) and PhI(CF₃O₂)₂ (5.2 g, 12 mmol). The mixture was refluxed

for 3h. After addition of water and extraction with DCM, the combined organic layers are washed with an aqueous saturated solution of NaHCO₃, and then water. The solution is dried (MgSO₄) and concentrated *in vacuo*. The pure product is obtained as a white powder by precipitation in hexane from the crude mixture (55%); **8** was identified by comparison of its spectral data to the literature ², R_f (Cy/ EtOAc, 8:2) 0.24; mp 108-110°C; δ_H (300 MHz, CDCl₃): 8.43 (1H, s, H₃); 7.88-8.07 (4H, m); 7.56-7.69 (2H, m); 5.02 (2H, s, H₂); δ_C (75 MHz, CDCl₃): 198.3 (s, C₁); 136.1 (s, C₂); 132.4 (s, C₄ or C₉); 130.7 (s, C₄ or C₉); 129.64 (d, C₃ or C₅); 129.57 (d, C₃ or C₅); 129.2 (d, C₇ or C₁₀); 129 (d, C₇ or C₁₀); 127.9 (d, C₈); 127.2 (d, C₆); 123.1 (d, C₁₁); 65.6 (d, C₂).

***tert*-butyl-4-[4-chloro-6(2-naphthalen-2-yl)-2-oxoethoxy]-1,3,5-triazin-2-ylloxy)
cyclopentane-1,3-diyl dicarbamate **9****




To a suspension of NaH (18 mg, 0.4 mmol) in THF (2 mL) was added a solution of alcohol **8** (80 mg, 0.4 mmol) in anhydrous THF (5 mL). The solution was stirred for 5 min at room temperature. Then, a solution of compound **7** (166 mg, 0.36 mmol) in THF (5 mL) was added. After stirring for 2h, the reaction is quenched with a saturated aqueous solution of NH₄Cl and extracted with DCM. The combined organic layers are dried (MgSO₄) and concentrated *in vacuo*. The crude mixture is submitted to FC on silica gel (Cyclohexane, AcOEt, 8:2) giving compound **9** as a white powder (26%); R_f (Cy/ EtOAc, 6:4) 0.43; mp 113-116°C; δ_H (300 MHz, CDCl₃): 8.47 (1H, s, H₁₂); 7.89-8.01 (4H, m, H₁₄, H₁₇, H₁₉, H₂₀); 7.57-7.68 (2H, m, H₁₅, H₁₆); 5.93 (1H, d (AB), *J* 16.2 Hz, H₉); 5.83 (1H, d (AB), *J* 16.2 Hz, H₉); 5.37 (2H, m, H₁, NH); 4.77 (1H, br s, NH); 3.93-4.06 (2H, m, H₂, H₄); 2.57 (1H, dt, *J* 8.2 Hz, *J* 13.8 Hz, H₃); 2.14-2.17 (2H, m, H₅); 1.42 (19H, m, CH₃ (tBu), H₃); δ_C (75 MHz, CDCl₃): 191.2 (s, C₁₀); 172.9 (s, C₈); 172.1 (s, C₆ or C₇); 171.6 (s, C₆ or C₇); 155.2 (s, CO_{Boc}); 136.1 (s, C₁₁); 132.5 (s, C₁₃ or C₁₈); 131.3 (s, C₁₃ or C₁₈); 129.8 (d); 129.7 (d); 129.2 (d); 129.1 (d); 128 (d); 127.3

² B. M. Trost, J. Xu, T. Schmidt *J. Am. Chem. Soc.* 2008, **130**, 11852.


(d); 123.3 (d); 83.2 (d, C₁); 79.8 (s, C_{iv Boc}); 69.8 (t, C₉); 55.9 (d, C₂); 48.7 (d, C₄); 36.8 (t, C₃ and C₅); 28.4 (q, C_{tBu}).


**2-[4-chloro-6(2,4-diaminocyclopentyloxy)1,3,5-triazin-2-yloxy)-1-naphthalen-2-yl]
ethanone 10**





A solution of **9** (16 mg, 0.026 mmol) was cooled in an ice-bath and HCl (g) was bubbled inside until the formation of a white precipitate (few minutes). The solution was concentrated *in vacuo* (13 mg); UV absorptions: λ_{max} (H₂O)/nm 290 and 350; δ_{H} (300 MHz, CD₃OD): 8.68 (1H, s, H₁₂); 8.11 (1H, d, *J* 8 Hz); 8.01 (2H, m); 7.97 (1H, d, *J* 8 Hz); 7.60-7.71 (2H, m); 6.12 (1H, d (AB), *J* 16.5 Hz, H₉); 6.02 (1H, d (AB), *J* 16.5 Hz, H₉); 5.64-5.71 (1H, m, H₁); 3.86-3.95 (2H, m, H₂, H₄); 2.72-2.76 (1H, m, H₃); 2.48-2.55 (1H, m, H₅); 2.35-2.42 (1H, m, H₅); 1.99-2.03 (1H, m, H₃); δ_{C} (75 MHz, CD₃OD): 193.6 (s, C₁₀); 174 (s, C₆ or C₇); 173.8 (s, C₆ or C₇); 172.9 (s, C₈); 137.7 (s, C₁₁); 134.1 (s, C₁₃ or C₁₈); 132.5 (s, C₁₃ or C₁₈); 131.5 (d); 131 (d); 130.4 (d); 130.1 (d); 129.1 (d); 128.4 (d); 124.2 (d); 80.4 (d, C₁); 71.8 (t, C₉); 55.9 (d, C₂); 36 (t, C₅); 34.6 (t, C₃); *m/z* (HRMS ESI): [MH]⁺ 414.1327 (Calculated for C₂₀H₂₁ClN₅O₃ 414.1327).


2. ^1H and ^{13}C NMR spectra of compounds 2, 4, 5, 7, 9 and 10






































































3. Superimposition of TROSY Spectra of tRNA^{Lys}₃ (black, 0.2 mM) and tRNA^{Lys}₃ (0.2 mM) mixed with compounds 5a-5g and 10 (red)


1:1




1:4




1:1




1:4




1:1




1:4




1:1




1:4




1:7




1:1




1:4




1:1




1:4




1:1




1:4




1:7



1:1



1:4



Additional data: selectivity study of **5b**.

tRNA_m^{Met} has a D-arm sequence identical to tRNA₃^{Lys}, but differs in its T-arm, in which the G65-C51 base pair is replaced by U65-A51. 1D NMR chemical shift perturbation (CSP) on tRNA_m^{Met} (Figure 1 below) was conducted with compound **5b**. For this tRNA, in 1D spectra, three NMR signals located in the T-arm could be followed during the titration (Figure 1). Contrary to the results obtained with tRNA₃^{Lys} (see Figure 2 below), almost no perturbations are observed on the T-arm signals of tRNA_m^{Met} when increasing the concentration of **5b**. Thus, **5b** clearly interacts with the T-arm of tRNA₃^{Lys}, and this interaction seems to be specific. Furthermore, no secondary binding site appears at similar (and even greater) concentrations for compounds **1** or **10**.




Fig. 1 a) Fluorescence titrations of compounds **5b** with tRNA_m^{Met}. The value of K_d are indicated with the 95% confidence interval in parenthesis. b) 1D ¹H NMR spectra showing the imino proton resonances of tRNA_m^{Met} (0.4 mM) when increasing concentration of compound **5b** is added. The tRNA:5b ratio are indicated on the left of the spectra.




Fig 2 1D ^1H NMR spectra showing the imino proton resonances of tRNA^{Lys3} (100 μM) when increasing concentration of compound **5b** is added. The tRNA:5b ratio are indicated on the left of the spectra.